Peptide Sciences Alternative: What Researchers Are Switching To in 2026

The Peptide Sciences shutdown occurred at a moment when mainstream scrutiny of peptide supply quality is higher than it has been in recent years. A 2026 Nature Medicine editorial specifically identified gray-market peptide sourcing — suppliers “labeled as being intended for research use, with unclear sources and quality control” — as a concern for the research community (Nat Med 32, 2693, 2026).

For independent researchers and institutional laboratory teams alike, the shutdown created a practical question: which vendors currently operating can be evaluated against the same documentation and sourcing criteria that established suppliers provided? The answer depends on how a researcher weighs each of the core supply-chain variables: COA documentation standards, manufacturing environment, sourcing transparency, and adherence to research-use-only framing throughout the supply chain.

The FDA PCAC review of compounding status and increased mainstream media coverage of peptide supply chains have both heightened the evidentiary bar for researchers selecting suppliers. Institutional review boards and independent researchers alike are asking harder questions about compound identity documentation before procurement.

Before switching suppliers, research teams working in this space typically evaluate vendors against the following criteria. Each represents a verifiable signal — not a marketing claim — that can be assessed before procurement.

Certificate of Analysis (COA) standards. A COA should include at minimum HPLC purity data and mass spectrometry (LC-MS) identity confirmation. A purity percentage without mass spec verification leaves compound identity unconfirmed. Lot-matching — the COA corresponding to the actual batch shipped, not a representative sample batch — is the second gate. Any supplier unable or unwilling to provide per-batch documentation presents a verification gap relevant to any laboratory relying on compound identity.

Manufacturing conditions. US-manufactured under ISO-5 cleanroom conditions represents the current standard for research-grade peptide supply. ISO-5 limits particulate contamination to standards comparable to sterile pharmaceutical manufacturing environments. For compounds used in in vitro or preclinical research, this manufacturing environment controls for a meaningful source of batch-to-batch variability.

Sourcing transparency. Researchers should be able to identify the manufacturing origin of the compound. Domestic manufacturers with verifiable facilities provide a documentation trail that gray-market imports cannot replicate. As the Nature Medicine editorial noted, gray-market supply chains create quality control gaps that are directly relevant to any researcher relying on compound identity for experimental reproducibility (Nat Med 32, 2693, 2026).

RUO framing. Any legitimate supplier of research peptides in the US operates under a For Research Use Only designation. This is the correct legal and ethical framework for the research peptide market. Suppliers making therapeutic claims, implying compounds are appropriate for human supplementation, or providing administration guidance are operating outside the RUO framework — which introduces regulatory and supply-chain risk for researchers sourcing from them.

Turnaround and support. For research timelines, domestic fulfillment with documented lead times and accessible scientific support reduces procurement friction. Gray-market importers often introduce customs delays, inconsistent lead times, and limited COA support.

All compounds referenced are for research use only. Comparisons reflect publicly documented sourcing and compliance practices; no therapeutic equivalence or clinical superiority is implied or stated. Researchers should independently verify supplier documentation before procurement.

Stackhaus Research sources compounds from Compass Bio Labs — a US-based manufacturer operating under ISO-5 controlled conditions. Every order includes a Certificate of Analysis covering HPLC purity and LC-MS mass confirmation, matched to the lot shipped. This is the documentation standard that institutional-grade procurement requires.

The compound catalog is RUO-only. That means:

• No therapeutic claims of any kind
• No human-use guidance, administration protocols, or supplementation framing
• No use of the word “clinical” to describe SHR products or their research context
• Every product labeled explicitly for research purposes only

This is the same sourcing and compliance framework researchers expect from institutional-grade suppliers, applied to a research-direct procurement model. Stackhaus Research currently maintains inventory in the following RUO research compounds:

• Retatrutide (RUO) — GLP-1/GIP/GcgR triple receptor agonist, studied in preclinical and Phase 3 metabolic research contexts
• MOTS-C — mitochondrially-encoded peptide, studied for metabolic and cellular energy regulation
• BPC-157 — gastric pentadecapeptide, studied for tissue repair mechanisms in preclinical models
• TB-500 (Thymosin Beta-4) — actin-binding peptide, studied for cell motility and tissue regeneration
• GHK-Cu — copper-binding tripeptide, studied for tissue remodeling and redox regulation
• SS-31 (Elamipretide) — cardiolipin-targeting tetrapeptide, studied for mitochondrial bioenergetics
• Thymosin Alpha-1 — immune-modulating peptide
• Semax · Selank · Epithalon · NAD+ · CJC-1295 · Ipamorelin — additional compounds in the current catalog

Full research catalog: stackhausresearch.com/peptides

All compounds supplied by Stackhaus Research are strictly For Research Use Only (RUO). They are not intended for administration to human or animal subjects, for self-administration, or as dietary supplements. They are not pharmaceutical agents carrying regulatory approval for any clinical or therapeutic indication. They have not been evaluated by any regulatory authority for safety or efficacy in any indication. Researchers ordering from Stackhaus Research are responsible for ensuring all use complies with applicable laws and institutional requirements in their jurisdiction.